Abstract 1271P
Background
Understanding the associates and causes of progression after first-line treatment in EGFR-mutant advanced NSCLC remains a critical yet elusive endeavor. In this study, we employed a comprehensive approach integrating machine learning classification and causal inference analysis to unveil the determinants of progression in this patient cohort.
Methods
Retrospective data from eleven academic centers were gathered to compile a cohort of EGFR mutant patients. Classical patient features, treatment characteristics, and the neutrophil to lymphocyte ratio (NLR) at the onset of first-line treatment were analyzed. Fifteen machine learning algorithms were employed to identify the optimal model, evaluated based on F1 score and area under the curve (AUC). Additionally, Linear Non-Gaussian Acyclic Model (LINGAM) was utilized for causal inference analysis to delineate the causal relationships driving progression.
Results
Among 333 patients initially evaluated, 205 cases were deemed suitable for machine learning analysis after accounting for missing data and follow-up duration. Linear discriminant analysis emerged as the most accurate model, achieving an AUC of 0.74 and an F1 score of 0.77. The top three influential variables identified by this model were smoking status, NLR category, and type of first-line treatment with variable importance scores of 1.2, 0.8, and 0.6, respectively. Moreover, LINGAM analysis revealed NLR category, smoking status, and gender as causal factors for progression, with causal estimate scores of -0.20, -0.17, and -0.04, respectively.
Conclusions
This study represents a pioneering effort in utilizing machine learning to explore the determinants of progression after first-line treatment in EGFR-mutant, advanced NSCLC. Our findings underscore the roles of smoking status, NLR category, and type of first-line treatment in driving progression. Furthermore, the causal inference analysis sheds light on smoking status, NLR category, and gender as causally significant factors. This understanding paves the way for elucidating the pathogenesis and developing novel therapeutic strategies for EGFR-mutant advanced NSCLC.
Clinical trial identification
Editorial acknowledgement
During the preparation of this work the authors used ChatGpt 3.5 in order to enhance readibility. After using this tool/service, the authors reviewed and edited the content as needed and take full responsibility for the content of the publication.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1270P - Lazertinib for patients with NSCLC harboring uncommon EGFR mutations: A single-arm, phase II multi-center trial
Presenter: Sehhoon Park
Session: Poster session 05
1272P - Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
Presenter: Jin-Ji Yang
Session: Poster session 05
Resources:
Abstract
1274P - Osimertinib versus first/second generation tyrosine kinase inhibitors as first-line therapy for metastatic EGFR-mutated non-small cell lung carcinoma: Overall survival using real-world data from TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 05
1276P - EXcellenT (exercise in extended oncogene addicted lung cancer in active treatment) trial: Preliminary results on impact of physical activity (PA) on emotional, metabolic and immune status
Presenter: Chiara Bennati
Session: Poster session 05
1277P - Optimising targeted therapy in NSCLC: A comprehensive analysis of oncogenic fusion mutations and co-mutation landscapes
Presenter: Li Dongge
Session: Poster session 05
1278P - Update of the INSPIRE study: Iruplinalkib versus crizotinib in ALK TKI-naïve locally advanced or metastatic ALK+ non-small cell lung cancer (NSCLC)
Presenter: Yuan-Kai Shi
Session: Poster session 05
1279P - First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study
Presenter: Yi-Long Wu
Session: Poster session 05
1280P - Effects of semaglutide on the exposure of alectinib in patients with NSCLC
Presenter: Daan Lanser
Session: Poster session 05
1281P - Impact of common germline variants on the toxicity profile and pharmacokinetics of alectinib
Presenter: Niels Heersche
Session: Poster session 05